{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:51:19Z","timestamp":1790949079963,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Single-fraction stereotactic body radiotherapy (SBRT) is an effective treatment option for patients with non-small cell lung cancer (NSCLC) who are ineligible for surgery. This study investigates long-term clinical outcomes, prognostic factors, and toxicity associated with high-dose single-fraction SBRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 110 patients with 116 NSCLC lesions treated with single-fraction SBRT between 2000 and 2023. Histologic subtypes included adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and CT-defined suspicious lesions without histological confirmation. Local control (LC), progression-free survival (PFS), and overall survival (OS) were assessed using Kaplan-Meier and Cox regression models. Toxicity was evaluated using CTCAE v4.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The most common dose was 30\u202fGy, prescribed in 76.7% of lesions. Among patients who received\u202f\u2265\u200930\u202fGy, LC at\u00a02, 3, and 5\u00a0years was 78%, 74%, and 68%; PFS was 63%, 49%, and 37%; and OS was 84%, 83%, and 60%, respectively. LC and PFS were significantly higher in patients treated with\u202f\u2265\u200930\u202fGy (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090.05).\n                    <\/jats:p>\n                    <jats:p>Acute pneumonitis occurred in 2\u00a0patients (1.8%), and 22\u00a0patients (20.0%) developed late-onset pneumonitis. Pneumonitis incidence was 26.8% in patients planned with 3D-CT, compared to 12.8% with DIBH or 4D-CT. No grade\u202f\u2265\u20093\u00a0toxicity was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High-dose (\u2265\u202f30\u202fGy) single-fraction SBRT provides excellent long-term tumor control with minimal toxicity with NSCLC. Advanced motion management techniques were associated with reduced pulmonary toxicity. A\u202f\u2265\u200930\u202fGy dose significantly improved LC, PFS, and OS. Higher Charlson Comorbidity Index (CCI) was associated with worse OS. These findings support the use of high-dose SF-SBRT in selected patients and highlight the need for individualized treatment planning. Prospective validation is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-025-02462-4","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T14:51:07Z","timestamp":1756997467000},"page":"307-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From protocol to practice: long-Term outcomes of single-Fraction stereotactic body radiotherapy for primary non-Small cell lung cancer"],"prefix":"10.1007","volume":"202","author":[{"given":"Kerem Tuna","family":"Tas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Lishewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Frosan","family":"Sheikhzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Smalec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Recknagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"W\u00fcndisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kirschbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Elsayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Engenhart-Cabillic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Zink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilke","family":"Vorwerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Adeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Gawish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"1","key":"2462_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.radonc.2017.05.012","volume":"124","author":"M Guckenberger","year":"2017","unstructured":"Guckenberger\u00a0M, Andratschke\u00a0N, Dieckmann\u00a0K, Hoogeman\u00a0MS, Hoyer\u00a0M, Hurkmans\u00a0C, Tanadini-Lang\u00a0S, Lartigau\u00a0E, M\u00e9ndez\u00a0RA, Senan\u00a0S, Verellen\u00a0D (2017) ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol 124(1):11\u201317. https:\/\/doi.org\/10.1016\/j.radonc.2017.05.012","journal-title":"Radiother Oncol"},{"issue":"5","key":"2462_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","volume":"7","author":"GMM Videtic","year":"2017","unstructured":"Videtic\u00a0GMM, Donington\u00a0J, Giuliani\u00a0M, Heinzerling\u00a0J, Karas\u00a0TZ, Kelsey\u00a0CR, Lally\u00a0BE, Latzka\u00a0K, Lo\u00a0SS, Moghanaki\u00a0D, Movsas\u00a0B, Rimner\u00a0A, Roach\u00a0M, Rodrigues\u00a0G, Shirvani\u00a0SM, Simone\u00a0CB 2nd, Timmerman\u00a0R, Daly\u00a0ME (2017) Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 7(5):295\u2013301. https:\/\/doi.org\/10.1016\/j.prro.2017.04.014","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"2462_CR3","first-page":"492","volume":"31","author":"K Rosenzweig","year":"2017","unstructured":"Rosenzweig\u00a0K (2017) Stereotactic body radiation therapy as an alternative to surgery in early-stage non-small-cell lung cancer. Oncology 31(6):492\u2013498","journal-title":"Oncology"},{"issue":"15","key":"2462_CR4","doi-asserted-by":"publisher","first-page":"155006","DOI":"10.1088\/1361-6560\/ab2e16","volume":"64","author":"G Palma","year":"2019","unstructured":"Palma\u00a0G, Monti\u00a0S, Thor\u00a0M, Rimner\u00a0A, Deasy\u00a0JO, Cella\u00a0L (2019) Spatial signature of dose patterns associated with acute radiation-induced lung damage in lung cancer patients treated with stereotactic body radiation therapy. Phys Med Biol 64(15):155006. https:\/\/doi.org\/10.1088\/1361-6560\/ab2e16","journal-title":"Phys Med Biol"},{"key":"2462_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.lungcan.2018.06.018","volume":"122","author":"MF Osti","year":"2018","unstructured":"Osti\u00a0MF, Agolli\u00a0L, Valeriani\u00a0M, Reverberi\u00a0C, Bracci\u00a0S, Marinelli\u00a0L, De Sanctis\u00a0V, Cortesi\u00a0E, Martelli\u00a0M, De Dominicis\u00a0C, Minniti\u00a0G, Nicosia\u00a0L (2018) 30\u202fGy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a\u00a0large series of patients with lung oligometastatic disease. Cancer Treat Res 122:165\u2013170. https:\/\/doi.org\/10.1016\/j.lungcan.2018.06.018 (Erratum in: Lung Cancer. 2021 Jul;157:168. https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.008)","journal-title":"Cancer Treat Res"},{"issue":"4","key":"2462_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1634\/theoncologist.2015-0477","volume":"21","author":"S Siva","year":"2016","unstructured":"Siva\u00a0S, Ball\u00a0D (2016) Curing operable stage\u00a0I non-small cell lung cancer with Stereotactic ablative body radiotherapy: the force awakens. Oncologist 21(4):393\u2013398. https:\/\/doi.org\/10.1634\/theoncologist.2015-0477","journal-title":"Oncologist"},{"issue":"5","key":"2462_CR7","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","volume":"103","author":"GM Videtic","year":"2019","unstructured":"Videtic\u00a0GM, Paulus\u00a0R, Singh\u00a0AK, Chang\u00a0JY, Parker\u00a0W, Olivier\u00a0KR, Timmerman\u00a0RD, Komaki\u00a0RR, Urbanic\u00a0JJ, Stephans\u00a0KL, Yom\u00a0SS, Robinson\u00a0CG, Belani\u00a0CP, Iyengar\u00a0P, Ajlouni\u00a0MI, Gopaul\u00a0DD, Gomez Suescun\u00a0JB, McGarry\u00a0RC, Choy\u00a0H, Bradley\u00a0JD (2019) Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a\u00a0randomized phase\u00a02\u00a0study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage\u00a0I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys 103(5):1077\u20131084. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.11.051","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2462_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2013.09.006","volume":"109","author":"F Sold\u00e0","year":"2013","unstructured":"Sold\u00e0\u00a0F, Lodge\u00a0M, Ashley\u00a0S, Whitington\u00a0A, Goldstraw\u00a0P, Brada\u00a0M (2013) Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a\u00a0surgical cohort. Radiother Oncol 109(1):1\u20137. https:\/\/doi.org\/10.1016\/j.radonc.2013.09.006","journal-title":"Radiother Oncol"},{"issue":"10","key":"2462_CR9","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/S1470-2045(21)00401-0","volume":"22","author":"JY Chang","year":"2021","unstructured":"Chang\u00a0JY, Mehran\u00a0RJ, Feng\u00a0L, Verma\u00a0V, Liao\u00a0Z, Welsh\u00a0JW, Lin\u00a0SH, O\u2019Reilly\u00a0MS, Jeter\u00a0MD, Balter\u00a0PA, McRae\u00a0SE, Berry\u00a0D, Heymach\u00a0JV, Roth\u00a0JA, STARS Lung Cancer Trials Group (2021) Stereotactic ablative radiotherapy for operable stage\u00a0I non-small-cell lung cancer (revised STARS): long-term results of a\u00a0single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol 22(10):1448\u20131457. https:\/\/doi.org\/10.1016\/S1470-2045(21)00401-0","journal-title":"Lancet Oncol"},{"issue":"1","key":"2462_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.radonc.2015.08.011","volume":"117","author":"AV Louie","year":"2015","unstructured":"Louie\u00a0AV, van Werkhoven\u00a0E, Chen\u00a0H, Smit\u00a0EF, Paul\u00a0MA, Widder\u00a0J, Groen\u00a0HJ, van den Borne\u00a0BE, De Jaeger\u00a0K, Slotman\u00a0BJ, Senan\u00a0S (2015) Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: results from the ROSEL multicenter randomized trial. Radiother Oncol 117(1):44\u201348. https:\/\/doi.org\/10.1016\/j.radonc.2015.08.011","journal-title":"Radiother Oncol"},{"key":"2462_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.radonc.2020.04.001","volume":"146","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger\u00a0M, Belka\u00a0C, Bezjak\u00a0A, Bradley\u00a0J, Daly\u00a0ME, DeRuysscher\u00a0D, Dziadziuszko\u00a0R, Faivre-Finn\u00a0C, Flentje\u00a0M, Gore\u00a0E, Higgins\u00a0KA, Iyengar\u00a0P, Kavanagh\u00a0BD, Kumar\u00a0S, Le Pechoux\u00a0C, Lievens\u00a0Y, Lindberg\u00a0K, McDonald\u00a0F, Ramella\u00a0S, Rengan\u00a0R, Ricardi\u00a0U, Rimner\u00a0A, Rodrigues\u00a0GB, Schild\u00a0SE, Senan\u00a0S, Simone\u00a0CB 2nd, Slotman\u00a0BJ, Stuschke\u00a0M, Videtic\u00a0G, Widder\u00a0J, Yom\u00a0SS, Palma\u00a0D (2020) Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: an ESTRO-ASTRO consensus statement. Radiother Oncol 146:223\u2013229. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.001","journal-title":"Radiother Oncol"},{"issue":"5","key":"2462_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson\u00a0ME, Pompei\u00a0P, Ales\u00a0KL, MacKenzie\u00a0CR (1987) A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J\u00a0Chronic Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"issue":"5","key":"2462_CR13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","volume":"103","author":"GM Videtic","year":"2019","unstructured":"Videtic\u00a0GM, Paulus\u00a0R, Singh\u00a0AK, Chang\u00a0JY, Parker\u00a0W, Olivier\u00a0KR, Timmerman\u00a0RD, Komaki\u00a0RR, Urbanic\u00a0JJ, Stephans\u00a0KL, Yom\u00a0SS, Robinson\u00a0CG, Belani\u00a0CP, Iyengar\u00a0P, Ajlouni\u00a0MI, Gopaul\u00a0DD, Gomez Suescun\u00a0JB, McGarry\u00a0RC, Choy\u00a0H, Bradley\u00a0JD (2019) Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a\u00a0randomized phase\u00a02\u00a0study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage\u00a0I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys 103(5):1077\u20131084. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.11.051","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2462_CR14","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ijrobp.2019.08.019","volume":"105","author":"AK Singh","year":"2019","unstructured":"Singh\u00a0AK, Gomez-Suescun\u00a0JA, Stephans\u00a0KL, Bogart\u00a0JA, Hermann\u00a0GM, Tian\u00a0L, Groman\u00a0A, Videtic\u00a0GM (2019) One versus three fractions of Stereotactic body radiation therapy for peripheral stage\u00a0I to II non-small cell lung cancer: a\u00a0randomized, multi-institution, phase\u00a02 trial. Int J Radiat Oncol Biol Phys 105(4):752\u2013759. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.08.019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2462_CR15","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/s0003-4975(02)04681-7","volume":"75","author":"RI Whyte","year":"2003","unstructured":"Whyte\u00a0RI, Crownover\u00a0R, Murphy\u00a0MJ, Martin\u00a0DP, Rice\u00a0TW, DeCamp\u00a0MM Jr, Rodebaugh\u00a0R, Weinhous\u00a0MS, Le\u00a0QT (2003) Stereotactic radiosurgery for lung tumors: preliminary report of a\u00a0phase\u00a0I trial. Ann Thorac Surg 75(4):1097\u20131101. https:\/\/doi.org\/10.1016\/s0003-4975(02)04681-7","journal-title":"Ann Thorac Surg"},{"issue":"8","key":"2462_CR16","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/01243894-200610000-00008","volume":"1","author":"QT Le","year":"2006","unstructured":"Le\u00a0QT, Loo\u00a0BW, Ho\u00a0A, Cotrutz\u00a0C, Koong\u00a0AC, Wakelee\u00a0H, Kee\u00a0ST, Constantinescu\u00a0D, Whyte\u00a0RI, Donington\u00a0J (2006) Results of a\u00a0phase\u00a0I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J\u00a0Thorac Oncol 1(8):802\u2013809","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2462_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.21037\/tlcr.2018.06.10","volume":"8","author":"V Verma","year":"2019","unstructured":"Verma\u00a0V, Simone\u00a0CB 2nd (2019) Approaches to stereotactic body radiation therapy for large (\u2265\u202f5 centimeter) non-small cell lung cancer. Transl Lung Cancer Res 8(1):70\u201377. https:\/\/doi.org\/10.21037\/tlcr.2018.06.10","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"2462_CR18","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.21037\/tlcr-20-469","volume":"9","author":"RO Kowalchuk","year":"2020","unstructured":"Kowalchuk\u00a0RO, Waters\u00a0MR, Baliga\u00a0S, Richardson\u00a0KM, Spencer\u00a0KM, Larner\u00a0JM, Kersh\u00a0CR (2020) Stereotactic body radiation therapy for empirically treated hypermetabolic lung lesions: a\u00a0single-institutional experience identifying the Charlson score as a\u00a0key prognostic factor. Transl Lung Cancer Res 9(5):1862\u20131872. https:\/\/doi.org\/10.21037\/tlcr-20-469","journal-title":"Transl Lung Cancer Res"},{"issue":"7 Suppl 3","key":"2462_CR19","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","volume":"2","author":"H Onishi","year":"2007","unstructured":"Onishi\u00a0H, Shirato\u00a0H, Nagata\u00a0Y, Hiraoka\u00a0M, Fujino\u00a0M, Gomi\u00a0K, Niibe\u00a0Y, Karasawa\u00a0K, Hayakawa\u00a0K, Takai\u00a0Y, Kimura\u00a0T, Takeda\u00a0A, Ouchi\u00a0A, Hareyama\u00a0M, Kokubo\u00a0M, Hara\u00a0R, Itami\u00a0J, Yamada\u00a0K, Araki\u00a0T (2007) Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage\u00a0I non-small cell lung cancer: updated results of 257 patients in a\u00a0Japanese multi-institutional study. J\u00a0Thorac Oncol 2(7 Suppl 3):S94\u2013S100. https:\/\/doi.org\/10.1097\/JTO.0b013e318074de34","journal-title":"J Thorac Oncol"},{"issue":"6","key":"2462_CR20","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/j.athoracsur.2015.04.113","volume":"100","author":"A Pennathur","year":"2015","unstructured":"Pennathur\u00a0A, Luketich\u00a0JD, Heron\u00a0DE, Schuchert\u00a0MJ, Bianco\u00a0V, Clump\u00a0D, Burton\u00a0S, Abbas\u00a0G, Gooding\u00a0WE, Ozhasoglu\u00a0C, Landreneau\u00a0RJ, Christie\u00a0NA (2015) Stereotactic radiosurgery\/stereotactic body radiotherapy for recurrent lung neoplasm: an analysis of outcomes in 100 patients. Ann Thorac Surg 100(6):2019\u20132024. https:\/\/doi.org\/10.1016\/j.athoracsur.2015.04.113","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"2462_CR21","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1080\/0284186X.2017.1295166","volume":"56","author":"H Tekatli","year":"2017","unstructured":"Tekatli\u00a0H, Tetar\u00a0SU, Nguyen\u00a0TK, Warner\u00a0A, Verbakel\u00a0WF, Palma\u00a0DA, Dahele\u00a0M, Gaede\u00a0S, Haasbeek\u00a0C, Spoelstra\u00a0FO, de Haan\u00a0PF, Slotman\u00a0BJ, Senan\u00a0S (2017) Optimizing SABR delivery for synchronous multiple lung tumors using volumetric-modulated arc therapy. Acta Oncol 56(4):548\u2013554. https:\/\/doi.org\/10.1080\/0284186X.2017.1295166","journal-title":"Acta Oncol"},{"issue":"1","key":"2462_CR22","first-page":"81","volume":"3","author":"AMS Kumar","year":"2014","unstructured":"Kumar\u00a0AMS, Woody\u00a0NM, Djemil\u00a0T, Videtic\u00a0GMM, Stephans\u00a0KL (2014) Synchronous non small cell lung cancer nodules treated with stereotactic body radiation therapy (SBRT). J\u00a0Radiosurg SBRT 3(1):81\u201388","journal-title":"J Radiosurg SBRT"},{"issue":"10","key":"2462_CR23","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1001\/jama.2020.0400","volume":"323","author":"TJ Royce","year":"2020","unstructured":"Royce\u00a0TJ, Thaker\u00a0NG, Agarwal\u00a0A (2020) Radiation oncology alternative payment model. JAMA 323(10):999. https:\/\/doi.org\/10.1001\/jama.2020.0400","journal-title":"JAMA"},{"issue":"5","key":"2462_CR24","doi-asserted-by":"publisher","first-page":"e767","DOI":"10.1016\/j.ijrobp.2010.10.074","volume":"81","author":"DJ Sher","year":"2011","unstructured":"Sher\u00a0DJ, Wee\u00a0JO, Punglia\u00a0RS (2011) Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 81(5):e767\u2013e774. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.10.074","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2462_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.radonc.2017.08.029","volume":"125","author":"J H\u00f6rner-Rieber","year":"2017","unstructured":"H\u00f6rner-Rieber\u00a0J, Bernhardt\u00a0D, Dern\u00a0J, K\u00f6nig\u00a0L, Adeberg\u00a0S, Paul\u00a0A, Heussel\u00a0CP, Kappes\u00a0J, Hoffmann\u00a0H, Herth\u00a0FJP, Debus\u00a0J, Warth\u00a0A, Rieken\u00a0S (2017) Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy. Radiother Oncol 125(2):317\u2013324. https:\/\/doi.org\/10.1016\/j.radonc.2017.08.029","journal-title":"Radiother Oncol"},{"issue":"12","key":"2462_CR26","doi-asserted-by":"publisher","first-page":"100598","DOI":"10.1016\/j.jtocrr.2023.100598","volume":"4","author":"AJ Iovoli","year":"2023","unstructured":"Iovoli\u00a0AJ, Prasad\u00a0S, Ma\u00a0SJ, Fekrmandi\u00a0F, Malik\u00a0NK, Fung-Kee-Fung\u00a0S, Farrugia\u00a0MK, Singh\u00a0AK (2023) Long-term survival and failure outcomes of single-fraction stereotactic body radiation therapy in early stage NSCLC. JTO Clin Res Rep 4(12):100598. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100598","journal-title":"JTO Clin Res Rep"},{"issue":"6","key":"2462_CR27","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.3390\/cancers15061648","volume":"15","author":"K Huang","year":"2023","unstructured":"Huang\u00a0K, Prasad\u00a0S, Ma\u00a0SJ, Iovoli\u00a0AJ, Farrugia\u00a0MK, Malik\u00a0NK, Singh\u00a0AK (2023) Comparison of survival outcomes of single- and five-fraction schedules of stereotactic body radiation therapy for early-stage central or peripheral NSCLC. Cancers 15(6):1648. https:\/\/doi.org\/10.3390\/cancers15061648","journal-title":"Cancers"},{"issue":"1","key":"2462_CR28","doi-asserted-by":"publisher","first-page":"15498","DOI":"10.1038\/s41598-019-51900-8","volume":"9","author":"L Nicosia","year":"2019","unstructured":"Nicosia\u00a0L, Reverberi\u00a0C, Agolli\u00a0L, Marinelli\u00a0L, De Sanctis\u00a0V, Valeriani\u00a0M, Osti\u00a0MF (2019) Long term results of single high dose Stereotactic Body Radiotherapy in the treatment of primary lung tumors. Sci Rep 9(1):15498. https:\/\/doi.org\/10.1038\/s41598-019-51900-8","journal-title":"Sci Rep"},{"issue":"2","key":"2462_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/s0360-3016(02)04504-2","volume":"56","author":"H Hof","year":"2003","unstructured":"Hof\u00a0H, Herfarth\u00a0KK, M\u00fcnter\u00a0M, Hoess\u00a0A, Motsch\u00a0J, Wannenmacher\u00a0M, Debus\u00a0JJ (2003) Stereotactic single-dose radiotherapy of stage\u00a0I non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 56(2):335\u2013341. https:\/\/doi.org\/10.1016\/s0360-3016(02)04504-2","journal-title":"Int J Radiat Oncol Biol Phys"}],"updated-by":[{"DOI":"10.1007\/s00066-025-02485-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000}}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02462-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-025-02462-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02462-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:06:26Z","timestamp":1772449586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-025-02462-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2462"],"URL":"https:\/\/doi.org\/10.1007\/s00066-025-02462-4","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The author\u2019s name Khaled Elsayad was incorrectly written as Khalid Elsayad, and the author\u2019s name Philipp Lishewski was incorrectly written as Phillip Lishewski.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00066-025-02485-x","URL":"https:\/\/doi.org\/10.1007\/s00066-025-02485-x","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.\u00a0Adeberg and Honoraria\/travel reimbursementAccuray Inc., AstraZeneca GmbH, Servier, Bristol Myers Squibb GmbH & Co., MSD, Novocure GmbH, Merck KGaA, Fakult\u00e4t Heidelberg, Fakult\u00e4t Marburg, Sanofi Genzyme, SA: Research cooperations Novocure GmbH. SA: Scientific AdvisoryAccuray Inc., Sanofi Genzyme, Servier, Novartis, Novocure GmbH, Merck KGaA. K.T.\u00a0Tas, P.\u00a0Lishewski, F.F.\u00a0Sheikhzadeh, E.\u00a0Smalec, N.\u00a0Recknagel, T.\u00a0W\u00fcndisch, A.\u00a0Holland, A.\u00a0Kirschbaum, K.\u00a0Elsayad, R.\u00a0Engenhart-Cabillic, K.\u00a0Zink, H.\u00a0Vorwerk and A.\u00a0Gawish declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"S. Adeberg and Honoraria\/travel reimbursementAccuray Inc., AstraZeneca GmbH, Servier, Bristol Myers Squibb GmbH & Co., MSD, Novocure GmbH, Merck KGaA, Fakult\u00e4t Heidelberg, Fakult\u00e4t Marburg, Sanofi Genzyme, SA: Research cooperations Novocure GmbH. SA: Scientific AdvisoryAccuray Inc., Sanofi Genzyme, Servier, Novartis, Novocure GmbH, Merck KGaA. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}